Back to Search Technologies

METHODS, COMPOSITIONS, AND SYSTEMS TO DETECT NON-SMALL CELL LUNG CANCER

Researchers at CZ Biohub SF and UCSF have developed novel methods for the early detection of non-small cell lung cancer.

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the U.S., with many cases diagnosed at an advanced stage, significantly reducing survival rates. Although low-dose chest CT (LDCT) scans are effective for early detection, their use is limited by cost, accessibility, and low participation, especially among eligible smokers. Additionally, LDCT screening guidelines do not currently cover never-smokers, a group that now accounts for up to 25% of new NSCLC cases. Additionally, LDCT scans have significant drawbacks, such as false positives and incidental findings. While liquid biopsy tests offer a non-invasive alternative, they currently lack the sensitivity needed for early detection, highlighting the need for new, scalable screening methods for at-risk individuals.

Stage of Research

This groundbreaking invention offers innovative methods, kits, devices, and systems for early detection and monitoring of non-small cell lung cancer (NSCLC) through cutting-edge genetic and immunologic biomarkers. By measuring the expression products of specific genes associated with NSCLC, this technology enables accurate identification of individuals at risk for or already diagnosed with NSCLC using a simple biological sample like blood or tissue. This invention can be utilized to develop PCRs, immunoassays, and expression arrays that can provide precise diagnostic tools to help guide treatment decisions, including surgery, chemotherapy, and targeted therapies. This invention can further utilize antibody detection by exposing patient samples to polypeptides encoded by the target genes using peptide display libraries (e.g., phage display) to discover novel NSCLC antigens and identify disease-specific autoantibodies. Overall, the invention supports early detection, monitoring, and treatment of NSCLC using scalable, biologically-based diagnostic tools.

Applications

Early Detection and Risk Assessment for NSCLC - This invention can be used to measure specific biomarkers in biological samples, allowing healthcare providers to identify individuals at high risk for non-small cell lung cancer (NSCLC) before symptoms appear, leading to earlier intervention and improved patient outcomes.
Personalized Treatment Monitoring for NSCLC - The invention enables continuous monitoring of NSCLC patients by detecting changes in biomarker levels over time, helping physicians assess treatment effectiveness, adjust therapies, and make data-driven decisions on surgery, chemotherapy, or targeted therapies.

Advantages

High Sensitivity and Accuracy - The invention leverages advanced genetic and immunologic techniques to offer highly sensitive and accurate detection of NSCLC biomarkers, reducing the likelihood of false positives or missed diagnoses.
Versatility and Comprehensive Application - The invention is versatile, applicable not only for early detection and risk assessment but also for ongoing monitoring, treatment decision-making, and the discovery of novel NSCLC antigens, enhancing its overall clinical utility.